D'autres prostaglandines ou médicaments comme l'ocytocine peuvent être utilisés.
OcytocineProstaglandines
Complications
5
#1
Quelles complications peuvent survenir avec le dinoprostone ?
Des complications comme la rupture utérine ou des saignements peuvent survenir.
Rupture utérineSaignements
#2
Comment gérer une surstimulation utérine ?
La gestion inclut l'arrêt du dinoprostone et une surveillance étroite des contractions.
Surstimulation utérineGestion des contractions
#3
Le dinoprostone peut-il entraîner des infections ?
Oui, il existe un risque accru d'infections utérines après son utilisation.
Infections utérinesRisques infectieux
#4
Quels signes indiquent une complication grave ?
Des douleurs abdominales sévères, des saignements ou des signes de choc nécessitent une attention immédiate.
Complications gravesSaignements
#5
Comment prévenir les complications liées à l'utilisation du dinoprostone ?
Une surveillance attentive et une évaluation des risques peuvent aider à prévenir les complications.
Prévention des complicationsSurveillance médicale
Facteurs de risque
5
#1
Quels sont les facteurs de risque pour l'utilisation du dinoprostone ?
Les antécédents de chirurgie utérine, les grossesses multiples et les infections sont des facteurs de risque.
Facteurs de risqueChirurgie utérine
#2
Les femmes âgées sont-elles à risque avec le dinoprostone ?
Oui, les femmes de plus de 35 ans peuvent avoir un risque accru de complications.
Âge maternelComplications
#3
Les antécédents de fausses couches augmentent-ils les risques ?
Oui, des antécédents de fausses couches peuvent augmenter le risque de complications.
Fausses couchesAntécédents médicaux
#4
Le surpoids est-il un facteur de risque pour le dinoprostone ?
Oui, le surpoids peut augmenter le risque de complications lors de l'utilisation.
SurpoidsComplications
#5
Les infections vaginales sont-elles un facteur de risque ?
Oui, les infections vaginales peuvent augmenter le risque d'infections après l'utilisation.
Infections vaginalesRisques infectieux
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dinoprostone : Questions médicales les plus fréquentes",
"headline": "Dinoprostone : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dinoprostone : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-15",
"dateModified": "2026-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dinoprostone"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Prostaglandines E",
"url": "https://questionsmedicales.fr/mesh/D011458",
"about": {
"@type": "MedicalCondition",
"name": "Prostaglandines E",
"code": {
"@type": "MedicalCode",
"code": "D011458",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.469.050.175.725.250"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dinoprostone",
"alternateName": "Dinoprostone",
"code": {
"@type": "MedicalCode",
"code": "D015232",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hubert Huras",
"url": "https://questionsmedicales.fr/author/Hubert%20Huras",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Perinatology, Jagiellonian University Medical College, Cracow, Poland."
}
},
{
"@type": "Person",
"name": "Guo-Qiang Sun",
"url": "https://questionsmedicales.fr/author/Guo-Qiang%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics, Maternity and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China."
}
},
{
"@type": "Person",
"name": "Ling Wang",
"url": "https://questionsmedicales.fr/author/Ling%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetric, Hubei Maternity and Child Health Hospital, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Mei Xiao",
"url": "https://questionsmedicales.fr/author/Mei%20Xiao",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetric, Hubei Maternity and Child Health Hospital, Wuhan, China."
}
},
{
"@type": "Person",
"name": "Rafael Hernández Pailos",
"url": "https://questionsmedicales.fr/author/Rafael%20Hern%C3%A1ndez%20Pailos",
"affiliation": {
"@type": "Organization",
"name": "Department of Obstetrics and Gynecology, La Mancha Centro Hospital, 13600 Alcazar de San Juan, Spain."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Safety of misoprostol vs dinoprostone for induction of labor: A systematic review and meta-analysis.",
"datePublished": "2023-08-28",
"url": "https://questionsmedicales.fr/article/37660506",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejogrb.2023.08.382"
}
},
{
"@type": "ScholarlyArticle",
"name": "Using dinoprostone slow release vaginal insert for cervical ripening in term-pregnancy with oligohydramnios.",
"datePublished": "2023-05-27",
"url": "https://questionsmedicales.fr/article/37245054",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jog.15665"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of dinoprostone versus cook cervical ripening balloon on induction in pregnancies complicated by small-for-gestational-age fetuses at term.",
"datePublished": "2024-07-21",
"url": "https://questionsmedicales.fr/article/39034273",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14767058.2024.2381584"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of fetal safety of vaginal Misoprostol tablet and Dinoprostone gel for induction of labor: An open-label randomized control trial.",
"datePublished": "2023-07-08",
"url": "https://questionsmedicales.fr/article/37421158",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/jog.15737"
}
},
{
"@type": "ScholarlyArticle",
"name": "Diagnostic accuracy of pre-induction cervical elastography, volume, length, and uterocervical angle for the prediction of successful induction of labor with dinoprostone.",
"datePublished": "2023-05-21",
"url": "https://questionsmedicales.fr/article/37210702",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00404-023-07076-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Médiateurs de l'inflammation",
"item": "https://questionsmedicales.fr/mesh/D018836"
},
{
"@type": "ListItem",
"position": 4,
"name": "Autacoïdes",
"item": "https://questionsmedicales.fr/mesh/D012898"
},
{
"@type": "ListItem",
"position": 5,
"name": "Éicosanoïdes",
"item": "https://questionsmedicales.fr/mesh/D015777"
},
{
"@type": "ListItem",
"position": 6,
"name": "Prostaglandines",
"item": "https://questionsmedicales.fr/mesh/D011453"
},
{
"@type": "ListItem",
"position": 7,
"name": "Prostaglandines E",
"item": "https://questionsmedicales.fr/mesh/D011458"
},
{
"@type": "ListItem",
"position": 8,
"name": "Dinoprostone",
"item": "https://questionsmedicales.fr/mesh/D015232"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dinoprostone - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dinoprostone",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dinoprostone",
"description": "Comment le dinoprostone est-il utilisé en obstétrique ?\nQuels tests précèdent l'administration de dinoprostone ?\nLe dinoprostone est-il utilisé pour des avortements médicaux ?\nQuelles sont les indications du dinoprostone ?\nLe dinoprostone est-il utilisé en cas de grossesse à risque ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dinoprostone",
"description": "Quels symptômes peuvent apparaître après l'administration de dinoprostone ?\nLe dinoprostone peut-il provoquer des effets secondaires ?\nComment reconnaître une réaction allergique au dinoprostone ?\nQuels signes indiquent une surstimulation utérine ?\nLe dinoprostone peut-il affecter le fœtus ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dinoprostone",
"description": "Comment prévenir les complications liées au dinoprostone ?\nY a-t-il des précautions à prendre avant l'utilisation ?\nLe dinoprostone est-il sûr pour toutes les patientes ?\nComment minimiser les effets secondaires du dinoprostone ?\nQuelles sont les recommandations pour l'utilisation du dinoprostone ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dinoprostone",
"description": "Comment le dinoprostone est-il administré ?\nQuelle est la posologie habituelle de dinoprostone ?\nLe dinoprostone nécessite-t-il une surveillance ?\nPeut-on combiner le dinoprostone avec d'autres médicaments ?\nQuelles alternatives au dinoprostone existent ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dinoprostone",
"description": "Quelles complications peuvent survenir avec le dinoprostone ?\nComment gérer une surstimulation utérine ?\nLe dinoprostone peut-il entraîner des infections ?\nQuels signes indiquent une complication grave ?\nComment prévenir les complications liées à l'utilisation du dinoprostone ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dinoprostone",
"description": "Quels sont les facteurs de risque pour l'utilisation du dinoprostone ?\nLes femmes âgées sont-elles à risque avec le dinoprostone ?\nLes antécédents de fausses couches augmentent-ils les risques ?\nLe surpoids est-il un facteur de risque pour le dinoprostone ?\nLes infections vaginales sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D015232#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le dinoprostone est-il utilisé en obstétrique ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est utilisé pour induire le travail chez les femmes enceintes à terme ou pour l'avortement."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de dinoprostone ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation clinique et un monitoring fœtal sont effectués avant l'administration."
}
},
{
"@type": "Question",
"name": "Le dinoprostone est-il utilisé pour des avortements médicaux ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est utilisé pour provoquer des avortements médicaux en début de grossesse."
}
},
{
"@type": "Question",
"name": "Quelles sont les indications du dinoprostone ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Indications incluent l'induction du travail et la gestion des fausses couches."
}
},
{
"@type": "Question",
"name": "Le dinoprostone est-il utilisé en cas de grossesse à risque ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être utilisé, mais avec prudence et sous surveillance médicale stricte."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent apparaître après l'administration de dinoprostone ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des contractions utérines, des douleurs abdominales et des nausées peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le dinoprostone peut-il provoquer des effets secondaires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets secondaires comme des vomissements et des diarrhées peuvent se produire."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique au dinoprostone ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent indiquer une allergie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surstimulation utérine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des contractions fréquentes et intenses, accompagnées de douleur, peuvent indiquer une surstimulation."
}
},
{
"@type": "Question",
"name": "Le dinoprostone peut-il affecter le fœtus ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets sur le fœtus sont possibles, nécessitant une surveillance attentive."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées au dinoprostone ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une évaluation rigoureuse et un suivi médical peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des précautions à prendre avant l'utilisation ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents médicaux et des allergies doivent être évalués avant l'utilisation."
}
},
{
"@type": "Question",
"name": "Le dinoprostone est-il sûr pour toutes les patientes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, il est contre-indiqué chez certaines patientes, comme celles avec des cicatrices utérines."
}
},
{
"@type": "Question",
"name": "Comment minimiser les effets secondaires du dinoprostone ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une administration prudente et un suivi des symptômes peuvent minimiser les effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour l'utilisation du dinoprostone ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivre les protocoles médicaux et les recommandations des professionnels de santé."
}
},
{
"@type": "Question",
"name": "Comment le dinoprostone est-il administré ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut être administré par voie vaginale ou orale, selon l'indication clinique."
}
},
{
"@type": "Question",
"name": "Quelle est la posologie habituelle de dinoprostone ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La posologie varie selon l'indication, généralement entre 0,5 et 2 mg."
}
},
{
"@type": "Question",
"name": "Le dinoprostone nécessite-t-il une surveillance ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance continue est nécessaire pour évaluer la réponse et les effets."
}
},
{
"@type": "Question",
"name": "Peut-on combiner le dinoprostone avec d'autres médicaments ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des combinaisons peuvent être utilisées, mais sous supervision médicale pour éviter les interactions."
}
},
{
"@type": "Question",
"name": "Quelles alternatives au dinoprostone existent ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "D'autres prostaglandines ou médicaments comme l'ocytocine peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le dinoprostone ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme la rupture utérine ou des saignements peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment gérer une surstimulation utérine ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion inclut l'arrêt du dinoprostone et une surveillance étroite des contractions."
}
},
{
"@type": "Question",
"name": "Le dinoprostone peut-il entraîner des infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque accru d'infections utérines après son utilisation."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une complication grave ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs abdominales sévères, des saignements ou des signes de choc nécessitent une attention immédiate."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications liées à l'utilisation du dinoprostone ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance attentive et une évaluation des risques peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour l'utilisation du dinoprostone ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de chirurgie utérine, les grossesses multiples et les infections sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "Les femmes âgées sont-elles à risque avec le dinoprostone ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les femmes de plus de 35 ans peuvent avoir un risque accru de complications."
}
},
{
"@type": "Question",
"name": "Les antécédents de fausses couches augmentent-ils les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de fausses couches peuvent augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un facteur de risque pour le dinoprostone ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le surpoids peut augmenter le risque de complications lors de l'utilisation."
}
},
{
"@type": "Question",
"name": "Les infections vaginales sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les infections vaginales peuvent augmenter le risque d'infections après l'utilisation."
}
}
]
}
]
}
Department of Obstetrics, Maternity and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
2017-12-21
Department of Nursing, Physiotherapy and Occupational Therapy, Faculty of Nursing, University of Castilla-La Mancha IDINE, Camilo José Cela, 14, 13071 Ciudad Real, Spain.
Department of Nursing, Physiotherapy and Occupational Therapy, Faculty of Nursing, University of Castilla-La Mancha IDINE, Av. de España, s/n, 02001 Albacete, Spain.
Pharmacological agents such as prostaglandins (dinoprostone and misoprostol) are commonly used to reduce the duration of labor and promote vaginal delivery. However, key safety considerations with its...
We found 39 RCTs comparing the outcomes of interest between misoprostol and dinoprostone. The pooled effect showed no statistically significant difference between the two groups in terms of cesarean s...
This systematic review and meta-analysis demonstrate that misoprostol and dinoprostone appear to have a similar safety profile....
The study purposed to evaluate the success rate of cervical ripening using dinoprostone controlled-release vaginal insert and reveal some factors relating to successful cervical ripening....
This cross-sectional study was conducted at Tu Du Hospital in Vietnam from December 2021 to August 2022. The study enrolled 200 pregnant women with gestational age ≥37 weeks diagnosed with oligohydram...
In total, the success rate of DCR achieved at 57.5% and the cesarean delivery rate was 46.5%. None of the severe side-effects and complications was present. Using multivariable logistic regression, th...
Cervical ripening using a dinoprostone vaginal insert is a potentially acceptable method in term pregnancy accompanying with oligohydramnios. The probability of SCR can be predicted on a careful asses...
To explore the complications and pregnancy outcomes of vaginal dinoprostone vs. Cook's double balloon for the induction of labor among pregnancies complicated by small-for-gestational-age (SGA) at ter...
This retrospective study included consecutive singleton pregnancies complicated by SGA treated at Fujian Maternity and Child Health Hospital between January 2017 and December 2021. The patients were d...
This study included 318 women [165 (aged 30.25 ± 4.72 years) and 153 (aged 28.80 ± 3.91 years) in the dinoprostone and Cook's balloon groups]. The dinoprostone group had a higher vaginal delivery rate...
In pregnant woman with pregnancies complicated by SGA, cervical ripening using dinoprostone were more likely to achieve vaginal delivery than those with Cook's balloon, and with a favorable complicati...
In modern obstetrics, need of labor induction is increasing along with increased caesarean deliveries. Major contributions for these operative deliveries are due to induction failure. This demands a p...
This was a single-center randomized controlled trial incorporating 140 term women, equally randomized to get either tablet Misoprostol or Dinoprostone gel. Fetal heart rate patterns were compared in b...
There were no statistically significant changes in fetal heart rate pattern in both Misoprostol and Dinoprostone groups. Vaginal deliveries were statistically higher in Misoprostol group. Neonatal par...
Misoprostol is a safe alternative to Dinoprostone gel for induction of labor and found to be more effective labor-inducing agent. In the background of higher caesarean rate, vaginal Misoprostol can be...
The study's aim is to define among a group of ultrasonographic cervical measurements a candidate parameter predictive of successful of induction of labor in term pregnancies with unfavorable cervix....
This prospective observational study included 141 pregnant women at term with an unfavorable cervix (Bishop score ≤ 6). All patients underwent clinical and ultrasonographic cervical evaluation before ...
The vaginal delivery rate was 74% (n = 93) and the cesarean section (CS) rate was 26% (n = 32). Sixteen patients who had a cesarean section due to fetal distress before the active phase of labor were ...
Cervical length, cervical elastography, cervical volume, and uterocervical angle measurements did not provide a clinically useful prediction of outcomes following labor induction in our study group wi...
Most guidelines propose inducing labor within 24 h following term (37 or more weeks of gestation) prelabor rupture of membranes (PROM). However, the exact timing for initiating induction within the 24...
This was a retrospective cohort study including singleton pregnancies with PROM and an unfavorable cervix (Bishop score < 6) in which labor was induced using vaginal dinoprostone. Women were divided i...
450 women were included, 146 (32.4%) of whom were induced within 6 h of PROM and 304 (67.6%) were induced within 6-24 h. Cesarean delivery rate (15.8% versus 29.3%, p = 0.002) and nonreassuring fetal ...
Induction of labor within 6 h with vaginal dinoprostone after PROM for singleton pregnancies with an unfavorable cervix (Bishop score < 6) significantly associated with less cesarean section, less non...
The Maternal and Perinatal Death Surveillance and Response (MPDSR) was introduced in Kenya in 2016 and implemented at Kiambu Level 5 Hospital (KL5H) three years later in 2019. During a routine MPDSR m...
We conducted a retrospective cohort study of women who gave birth at KL5H between January 2018 and December 2020. We defined the pre-intervention period as January 2018-June 2019, and the intervention...
We reviewed 411 patient records and carried out 12 key informant interviews. Mothers induced with misoprostol (IRR = 3.89; CI = 0.21-71.6) had an increased risk of death while mothers were less likely...
While the period immediately following the implementation of MPDSR at KL5H was associated with an increased risk of death, the switch to dinoprostone for labour induction was associated with a lower r...
To compare the efficacy of the controlled-release dinoprostone delivery system (PROPESS) and Cook's double balloon catheter (DBC) plus oxytocin as induction treatment....
A total of 197 term pregnant women with unfavorable cervix were admitted for scheduled induction and enrolled retrospectively (PROPESS, 113; Cook's DBC plus oxytocin, 84). The main birth outcomes were...
The choice of PROPESS was associated with the success of cervical ripening at 24 h after (adjusted odds ratio (OR) 2.17, 95% confidence interval (CI) 1.11-4.26, p = 0.024) and increased the rate of va...
Our findings suggest the possibility of slight advantages of PROPESS for scheduled induction of labor. In women with early term and extremely low Bishop scores, Cook's DBC plus oxytocin may be a super...
The rates of labor induction and cesarean delivery is rising worldwide. With the confluence of these trends, the labor induction rate in trials of labor after cesarean can be as high as 27-32.7%. Indu...
The electronic medical records of women who delivered between January 2018 to September 2022 in a Malaysian university hospital were screened to identify cases of IOLAC. A case is classified as a comp...
Electronic medical records of 19,064 women were screened. 819 IOLAC cases and 98 cases with composite adverse outcomes were identified. Maternal height, ethnicity, previous vaginal delivery, indicatio...
Shorter women and IOLAC by vaginal dinoprostone compared to Foley balloon were independently predictive of composite of adverse outcome....
Fetal growth restriction (FGR) affects about 3%-5% of term pregnancies. If prenatally detected and anterograde umbilical artery flow is preserved (stage I), it is recommended to deliver at term (≥ 37+...
This will be an open-labelled, randomised, parallel-group clinical trial to be held in five Spanish maternities. Women aged ≥18 years with singleton pregnancies complicated with stage I FGR (defined a...
The trial was registered in the European Union drug regulating authorities' clinical trials database (EUDRACT) (2021-001726-22) and received approval from the local Research Ethics Committee (21/728) ...
V.1.1, 18 May 2023....
EUDRACT 2021-001726-22 and NCT05774236....